Delhaize Group press release - Delhaize Group announces result of the adjourned bondholders meeting
Feb 08, 2016 07:05 am UTC| Business
BRUSSELS, Belgium, Feb. 8, 2016 -- On 5 February 2016, an adjourned meeting was held for the holders of the 4.25% Bonds due 19 October 2018 to approve the change of issuer and to consent to various technical amendments in...
Malic Acid Market Size To Reach USD 0.20 Billion By 2020 : Radiant Insights,Inc
Feb 08, 2016 07:00 am UTC| Business
San Francisco, Feb. 08, 2016 -- Global Malic Acid Market is expected to reach USD 0.20 billion by 2020. Increasing acidulant and artificial flavorant demand in food beverage industries is expected to drive the global...
Medigus to Begin Clinical Study in China for CFDA Regulatory Clearance
Feb 08, 2016 07:00 am UTC| Business
Medigus receives first purchase order from Golden Grand-Medical Instruments Ltd. to advance commercial agreement Study results to be used for CFDA regulatory clearance process OMER, Israel, Feb. 08, 2016 -- Medigus...
DBV Technologies to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
Feb 08, 2016 06:58 am UTC| Business
MONTROUGE, France, Feb. 8, 2016 -- DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that Charles Ruban, Chief...
VALNEVA Signs New R&D Collaboration with GlaxoSmithKline for the EB66(r) Cell Line
Feb 08, 2016 06:08 am UTC| Business
Valneva to supply process development services for EB66-based Influenza vaccines Advanced Development program sponsored by the US Department of Health and Human Services Valneva to receive research fees under the...
INNATE PHARMA : Start of Phase I clinical trial of monalizumab in combination with durvalumab
Feb 08, 2016 06:06 am UTC| Business
Multicenter, open-label, dose-escalation and cohort-expansion Phase I study of durvalumab in combination with monalizumab in patients with solid tumors; Trial performed by AstraZeneca/MedImmune in the United States and...
Feb 08, 2016 06:00 am UTC| Business
MONT-SAINT-GUIBERT, Belgium, Feb. 08, 2016 -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular...